These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 28446646)

  • 21. Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington's disease: a review of clinical trial data.
    Claassen DO; Philbin M; Carroll B
    Expert Opin Pharmacother; 2019 Dec; 20(18):2209-2221. PubMed ID: 31613641
    [No Abstract]   [Full Text] [Related]  

  • 22. Efficacy and safety of valbenazine in Japanese patients with tardive dyskinesia: A multicenter, randomized, double-blind, placebo-controlled study (J-KINECT).
    Horiguchi J; Watanabe K; Kondo K; Iwatake A; Sakamoto H; Susuta Y; Masui H; Watanabe Y
    Psychiatry Clin Neurosci; 2022 Nov; 76(11):560-569. PubMed ID: 36114799
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and Safety of Fixed-Dose Deutetrabenazine in Children and Adolescents for Tics Associated With Tourette Syndrome: A Randomized Clinical Trial.
    Coffey B; Jankovic J; Claassen DO; Jimenez-Shahed J; Gertz BJ; Garofalo EA; Stamler DA; Wieman M; Savola JM; Gordon MF; Alexander JK; Barkay H; Harary E
    JAMA Netw Open; 2021 Oct; 4(10):e2129397. PubMed ID: 34661664
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease.
    Frank S; Anderson KE; Fernandez HH; Hauser RA; Claassen DO; Stamler D; Factor SA; Jimenez-Shahed J; Barkay H; Wilhelm A; Alexander JK; Chaijale N; Barash S; Savola JM; Gordon MF; Chen M
    Neurol Ther; 2024 Jun; 13(3):655-675. PubMed ID: 38557959
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effects of valbenazine on tardive dyskinesia in older and younger patients.
    Sajatovic M; Alexopoulos GS; Burke J; Farahmand K; Siegert S
    Int J Geriatr Psychiatry; 2020 Jan; 35(1):69-79. PubMed ID: 31617235
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Crushing deutetrabenazine for treatment of tardive dyskinesia in a patient with severe orofacial symptoms: A case report.
    Wietholter JP; Sizemore J; Piechowski K
    Am J Health Syst Pharm; 2020 Sep; 77(18):1477-1481. PubMed ID: 32761113
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.
    Josiassen RC; Kane JM; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):61-68. PubMed ID: 28839341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial.
    ; Frank S; Testa CM; Stamler D; Kayson E; Davis C; Edmondson MC; Kinel S; Leavitt B; Oakes D; O'Neill C; Vaughan C; Goldstein J; Herzog M; Snively V; Whaley J; Wong C; Suter G; Jankovic J; Jimenez-Shahed J; Hunter C; Claassen DO; Roman OC; Sung V; Smith J; Janicki S; Clouse R; Saint-Hilaire M; Hohler A; Turpin D; James RC; Rodriguez R; Rizer K; Anderson KE; Heller H; Carlson A; Criswell S; Racette BA; Revilla FJ; Nucifora F; Margolis RL; Ong M; Mendis T; Mendis N; Singer C; Quesada M; Paulsen JS; Brashers-Krug T; Miller A; Kerr J; Dubinsky RM; Gray C; Factor SA; Sperin E; Molho E; Eglow M; Evans S; Kumar R; Reeves C; Samii A; Chouinard S; Beland M; Scott BL; Hickey PT; Esmail S; Fung WL; Gibbons C; Qi L; Colcher A; Hackmyer C; McGarry A; Klos K; Gudesblatt M; Fafard L; Graffitti L; Schneider DP; Dhall R; Wojcieszek JM; LaFaver K; Duker A; Neefus E; Wilson-Perez H; Shprecher D; Wall P; Blindauer KA; Wheeler L; Boyd JT; Houston E; Farbman ES; Agarwal P; Eberly SW; Watts A; Tariot PN; Feigin A; Evans S; Beck C; Orme C; Edicola J; Christopher E
    JAMA; 2016 Jul; 316(1):40-50. PubMed ID: 27380342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deutetrabenazine: Treatment of hyperkinetic aspects of Huntington's disease, tardive dyskinesia and Tourette syndrome.
    Paton DM
    Drugs Today (Barc); 2017 Feb; 53(2):89-102. PubMed ID: 28387387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and Efficacy of Flexible-Dose Deutetrabenazine in Children and Adolescents With Tourette Syndrome: A Randomized Clinical Trial.
    Jankovic J; Coffey B; Claassen DO; Jimenez-Shahed J; Gertz BJ; Garofalo EA; Stamler DA; Wieman M; Savola JM; Gordon MF; Alexander J; Barkay H; Harary E
    JAMA Netw Open; 2021 Oct; 4(10):e2128204. PubMed ID: 34609495
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea.
    Frank S; Stamler D; Kayson E; Claassen DO; Colcher A; Davis C; Duker A; Eberly S; Elmer L; Furr-Stimming E; Gudesblatt M; Hunter C; Jankovic J; Kostyk SK; Kumar R; Loy C; Mallonee W; Oakes D; Scott BL; Sung V; Goldstein J; Vaughan C; Testa CM;
    JAMA Neurol; 2017 Aug; 74(8):977-982. PubMed ID: 28692723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia.
    Dorfman BJ; Jimenez-Shahed J
    Expert Rev Neurother; 2021 Jan; 21(1):9-20. PubMed ID: 33174440
    [No Abstract]   [Full Text] [Related]  

  • 33. Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.
    Niemann N; Jankovic J
    Drugs; 2018 Apr; 78(5):525-541. PubMed ID: 29484607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study.
    Hauser RA; Barkay H; Fernandez HH; Factor SA; Jimenez-Shahed J; Gross N; Marinelli L; Wilhelm A; Alexander J; Gordon MF; Savola JM; Anderson KE
    Front Neurol; 2022; 13():773999. PubMed ID: 35280262
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Phase 3, 1-Year, Open-Label Trial of Valbenazine in Adults With Tardive Dyskinesia.
    Marder SR; Singer C; Lindenmayer JP; Tanner CM; Comella CL; Verghese C; Jimenez R; Liang GS; Burke J; OʼBrien CF
    J Clin Psychopharmacol; 2019; 39(6):620-627. PubMed ID: 31688452
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective.
    Citrome L
    Expert Rev Neurother; 2018 Apr; 18(4):323-332. PubMed ID: 29557243
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Deuterium Tetrabenazine for Tardive Dyskinesia.
    Cummings MA; Proctor GJ; Stahl SM
    Clin Schizophr Relat Psychoses; 2018 Jan; 11(4):214-220. PubMed ID: 29341821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Deutetrabenazine (Austedo) for Huntington's chorea and tardive dyskinesia.
    Med Lett Drugs Ther; 2018 Apr; 60(1545):65-68. PubMed ID: 29667946
    [No Abstract]   [Full Text] [Related]  

  • 39. VMAT2 Inhibitors: New Drugs for the Treatment of Tardive Dyskinesia.
    Kim AP; Baker DE; Levien TL
    Consult Pharm; 2018 Apr; 33(4):201-209. PubMed ID: 29609698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FDA-Approved Medications to Treat Tardive Dyskinesia.
    McEvoy JP
    J Clin Psychiatry; 2019 Dec; 81(1):. PubMed ID: 31851437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.